Evidence map›Paper›PMID 40919100›Full record

ArticleOpen research Europe2025

When artificial intelligence meets protein research.

Sonia Longhi, Salvador Ventura, Sandra Macedo-Ribeiro, Leandro G Radusky, Jovana Kovačević, R Gonzalo Parra, Miguel A Andrade-Navarro, Andrey V Kajava, Zuzana Bednáriková, Alexander Monzon and 1 more

Abstract readLetter
In one paragraph

Article in Open research Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Artificial Intelligence Across the Drug Development Lifecycle.Medical sciences (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sonia LonghiAix Marseille University, Marseille, Provence-Alpes-Côte d'Azur, France.ORCID https://orcid.org/0000-0002-6829-6771
Salvador VenturaAutonomous University of Barcelona Institute of Biotechnology and Biomedicine, Bellaterra, Catalonia, Spain.
Sandra Macedo-RibeiroUniversidade do Porto Instituto de Investigacao e Inovacao em Saude, Porto, Porto District, Portugal.
Leandro G RaduskyMimark Diagnostics S.L., Parc Cientific Barcelona, Barcelona, Catalonia, Spain.
Jovana KovačevićUniversity of Belgrade Faculty of Mathematics, Belgrade, Serbia.
R Gonzalo ParraLife Sciences Department, Barcelona Supercomputing Center, Barcelona, Barcelona, Spain.
Miguel A Andrade-NavarroJohannes Gutenberg University Mainz Institute of Organismic and Molecular Evolution, Mainz, Rhineland-Palatinate, Germany.ORCID https://orcid.org/0000-0001-6650-1711
Andrey V KajavaAix Marseille University, Marseille, Provence-Alpes-Côte d'Azur, France.
Zuzana BednárikováInstitute of Experimental Physics Slovak Academy of Sciences, Košice, Košice Region, Slovakia.ORCID https://orcid.org/0000-0003-0837-9564
Alexander MonzonUniversity of Padua Department of Biomedical Sciences, Padua, Veneto, Italy.ORCID https://orcid.org/0000-0003-0362-8218
Rita VilaçaREQUIMTE LAQV Porto, Porto, Porto District, Portugal.ORCID https://orcid.org/0000-0002-2342-6886

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2024 Nobel Prizes in Chemistry and Physics mark a watershed moment in the convergence of artificial intelligence (AI) and molecular biology. This article explores how AI, particularly deep learning and neural networks, has revolutionized protein science through breakthroughs in structure prediction and computational design. It highlights the contributions of 2024 Nobel laureates John Hopfield, Geoffrey Hinton, David Baker, Demis Hassabis, and John Jumper, whose foundational work laid the groundwork for AI tools such as AlphaFold. These tools are transforming our understanding of protein folding, and the dynamics of non-globular proteins, including intrinsically disordered proteins. While AI-driven methods have made predicting protein structures faster and more accessible, they also underscore ongoing scientific challenges, including the dynamics of protein folding and amyloid aggregation. European initiatives, such as the COST Actions NGP-net (BM1405) and ML4NGP (CA21160), are spearheading efforts to bridge these gaps by integrating AI and experimental data in the study of non-globular proteins. Together, these developments signal a transformative shift in biology, paving the way for novel discoveries in medicine, biotechnology, and materials science.

Indexed as

artificial intelligencebioinformaticsdeep learningmachine learningnon-globular proteinsprotein foldingstructural biology

Identifiers

PMID40919100
PMCPMC12413608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.